{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T02:33:20Z","timestamp":1773369200486,"version":"3.50.1"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"33","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>The cell wall skeleton of Bacillus Calmette\u2013Gu\u00e9rin (BCG-CWS) is a bioactive component that is a strong immune adjuvant for cancer immunotherapy. BCG-CWS activates the innate immune system through various pattern recognition receptors and is expected to elicit antigen-specific cellular immune responses when co-administered with tumor antigens. To determine the recommended dose (RD) of BCG-CWS based on its safety profile, we conducted a phase I dose-escalation study of BCG-CWS in combination with WT1 peptide for patients with advanced cancer.<\/jats:p>\n            <jats:p>The primary endpoint was the proportion of treatment-related adverse events (AEs) at each BCG-CWS dose. The secondary endpoints were immune responses and clinical effects. A BCG-CWS dose of 50, 100, or 200\u200a\u03bcg\/body was administered intradermally on days 0, 7, 21, and 42, followed by 2\u200amg of WT1 peptide on the next day. For the escalation of a dose level, 3\u200a+\u200a3 design was used.<\/jats:p>\n            <jats:p>Study subjects were 18 patients with advanced WT1-expressing cancers refractory to standard anti-cancer therapies (7 melanoma, 5 colorectal, 4 hepatobiliary, 1 ovarian, and 1 lung). Dose-limiting toxicity occurred in the form of local skin reactions in 2 patients at a dose of 200\u200a\u03bcg although no serious treatment-related systemic AEs were observed. Neutrophils and monocytes transiently increased in response to BCG-CWS. Some patients demonstrated the induction of the CD4<jats:sup>+<\/jats:sup> T cell subset and its differentiation from the na\u00efve to memory phenotype, resulting in a tumor response.<\/jats:p>\n            <jats:p>The RD of BCG-CWS was determined to be 100\u200a\u03bcg\/body. This dose was well tolerated and showed promising clinical effects with the induction of an appropriate immune response.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000016771","type":"journal-article","created":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T14:47:09Z","timestamp":1565880429000},"page":"e16771","source":"Crossref","is-referenced-by-count":37,"title":["Immune adjuvant therapy using Bacillus Calmette\u2013Gu\u00e9rin cell wall skeleton (BCG-CWS) in advanced malignancies"],"prefix":"10.1097","volume":"98","author":[{"given":"Sumiyuki","family":"Nishida","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine and Clinical Immunology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Tsuboi","sequence":"additional","affiliation":[{"name":"Department of Cancer Immunotherapy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Tanemura","sequence":"additional","affiliation":[{"name":"Department of Dermatology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshinori","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Department of Cancer Immunology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Shirakata","sequence":"additional","affiliation":[{"name":"Department of Cancer Immunotherapy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soyoko","family":"Morimoto","sequence":"additional","affiliation":[{"name":"Department of Cancer Immunotherapy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumihiro","family":"Fujiki","sequence":"additional","affiliation":[{"name":"Department of Cancer Immunology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Hosen","sequence":"additional","affiliation":[{"name":"Department of Cancer Stem Cell Biology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Oji","sequence":"additional","affiliation":[{"name":"Department of Functional Diagnostic Science, Osaka University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Kumanogoh","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Clinical Immunology"},{"name":"Department of Immunopathology, Immunology Frontier Research Center, Osaka University, Suita, Osaka"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Kawase","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Clinical Immunology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Oka","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Clinical Immunology"},{"name":"Department of Cancer Stem Cell Biology"},{"name":"Department of Immunopathology, Immunology Frontier Research Center, Osaka University, Suita, Osaka"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Azuma","sequence":"additional","affiliation":[{"name":"Hokkaido University, Sapporo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Morita","sequence":"additional","affiliation":[{"name":"Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruo","family":"Sugiyama","sequence":"additional","affiliation":[{"name":"Department of Cancer Immunology"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230914","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1038\/nm.3409","article-title":"Key roles of adjuvants in modern vaccines","volume":"19","author":"Reed","year":"2013","journal-title":"Nat Med"},{"key":"R2-20230914","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1098\/rstb.2011.0106","article-title":"Innate immunity and adjuvants","volume":"366","author":"Akira","year":"2011","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"R3-20230914","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/intimm\/dxw015","article-title":"Vaccine adjuvants as potential cancer immunotherapeutics","volume":"28","author":"Temizoz","year":"2016","journal-title":"Int Immunol"},{"key":"R4-20230914","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrc.2016.16","article-title":"Vaccines for established cancer: overcoming the challenges posed by immune evasion","volume":"16","author":"van der Burg","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"R6-20230914","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1348-0421.1971.tb00569.x","article-title":"Adjuvanticity of mycobacterial cell walls","volume":"15","author":"Azuma","year":"1971","journal-title":"Jap J Microbiol"},{"key":"R7-20230914","doi-asserted-by":"crossref","first-page":"6883","DOI":"10.1128\/IAI.68.12.6883-6890.2000","article-title":"Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Gu\u00e9rin: involvement of toll-like receptors","volume":"68","author":"Tsuji","year":"2000","journal-title":"Infect Immun"},{"key":"R8-20230914","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1128\/IAI.71.8.4238-4249.2003","article-title":"Simultaneous blocking of human Toll-like receptors 2 and 4 suppresses myeloid dendritic cell activation induced by Mycobacterium bovis bacillus Calmette-Gu\u00e9rin peptidoglycan","volume":"71","author":"Uehori","year":"2003","journal-title":"Infect Immun"},{"key":"R9-20230914","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1084\/jem.20091750","article-title":"Direct recognition of the mycobacterial glycolipid, trehalose dimycolate, by C-type lectin Mincle","volume":"206","author":"Ishikawa","year":"2009","journal-title":"J Exp Med"},{"key":"R10-20230914","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.immuni.2014.08.005","article-title":"Dectin-2 is a direct receptor for mannose-capped lipoarabinomannan of mycobacteria","volume":"41","author":"Yonekawa","year":"2014","journal-title":"Immunity"},{"key":"R11-20230914","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/S1567-5769(01)00071-6","article-title":"Interferon gamma-producing ability in blood lymphocytes of patients with lung cancer through activation of the innate immune system by BCG cell wall skeleton","volume":"1","author":"Matsumoto","year":"2001","journal-title":"Int Immunopharmacol"},{"key":"R12-20230914","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1158\/0008-5472.CAN-03-1518","article-title":"Adjuvant-mediated tumor regression and tumor-specific cytotoxic response are impaired in MyD88-deficient mice","volume":"64","author":"Akazawa","year":"2004","journal-title":"Cancer Res"},{"key":"R13-20230914","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.imlet.2004.12.002","article-title":"Gene-inducing program of human dendritic cells in response to BCG cell-wall skeleton (CWS), which reflects adjuvancy required for tumor immunotherapy","volume":"98","author":"Ishii","year":"2005","journal-title":"Immunol Lett"},{"key":"R14-20230914","doi-asserted-by":"crossref","first-page":"7465","DOI":"10.1158\/1078-0432.CCR-06-1840","article-title":"Enhancement of immunologic tumor regression by intratumoral administration of dendritic cells in combination with cryoablative tumor pretreatment and Bacillus Calmette-Guerin cell wall skeleton stimulation","volume":"12","author":"Udagawa","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R15-20230914","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s00262-003-0498-0","article-title":"WT1 peptide vaccination combined with BCG-CWS is more efficient for tumor eradication than WT1 peptide vaccination alone","volume":"53","author":"Nakajima","year":"2004","journal-title":"Cancer Immunol Immunother"},{"key":"R16-20230914","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/1097-0142(197904)43:4<1314::AID-CNCR2820430420>3.0.CO;2-6","article-title":"Adjuvant immunotherapy of lung cancer with BCG cell wall skeleton (BCG-CWS)","volume":"43","author":"Yamamura","year":"1979","journal-title":"Cancer"},{"key":"R17-20230914","first-page":"3262","article-title":"Nonspecific adjuvant immunotherapy of lung cancer with cell wall skeleton of Mycobacterium bovis Bacillus Calmette-Gu\u00e9rin","volume":"39","author":"Yasumoto","year":"1979","journal-title":"Cancer Res"},{"key":"R18-20230914","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/BF00205355","article-title":"Postoperative adjuvant immunotherapy of gastric cancer with BCG-cell wall skeleton. 3- to 6-year follow up of a randomized clinical trial","volume":"14","author":"Ochiai","year":"1983","journal-title":"Cancer Immunol Immunother"},{"key":"R19-20230914","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s00595-008-3826-3","article-title":"Innate immune therapy with a Bacillus Calmette-Gu\u00e9rin cell wall skeleton after radical surgery for non-small cell lung cancer: a case-control study","volume":"39","author":"Kodama","year":"2009","journal-title":"Surg Today"},{"key":"R20-20230914","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/nrc3670","article-title":"Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy","volume":"14","author":"Coulie","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"R21-20230914","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","article-title":"The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research","volume":"15","author":"Cheever","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R22-20230914","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/0092-8674(90)90601-A","article-title":"Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms\u2019 tumor locus","volume":"60","author":"Call","year":"1990","journal-title":"Cell"},{"key":"R23-20230914","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1182\/blood.V84.9.3071.3071","article-title":"WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia","volume":"84","author":"Inoue","year":"1994","journal-title":"Blood"},{"key":"R24-20230914","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/modpathol.3800588","article-title":"Immunohistochemical detection of WT1 protein in a variety of cancer cells","volume":"19","author":"Nakatsuka","year":"2006","journal-title":"Mod Pathol"},{"key":"R25-20230914","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/jjco\/hyp194","article-title":"WT1 (Wilms\u2019 Tumor Gene 1): biology and cancer immunotherapy","volume":"40","author":"Sugiyama","year":"2010","journal-title":"Jpn J Clin Oncol"},{"key":"R26-20230914","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1182\/blood.V91.8.2969.2969_2969_2976","article-title":"Wilms\u2019 tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells","volume":"91","author":"Inoue","year":"1998","journal-title":"Blood"},{"key":"R27-20230914","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1182\/blood-2005-04-1656","article-title":"AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation with the Wilms tumor gene","volume":"107","author":"Nishida","year":"2006","journal-title":"WT1 Blood"},{"key":"R28-20230914","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1038\/sj.onc.1209455","article-title":"Antiapoptotic function of 17AA(+)WT1 (Wilms\u2019 tumor gene) isoforms on the intrinsic apoptosis pathway","volume":"25","author":"Ito","year":"2006","journal-title":"Oncogene"},{"key":"R29-20230914","doi-asserted-by":"crossref","first-page":"5852","DOI":"10.1038\/ncomms6852","article-title":"The Wilms\u2019 tumour suppressor Wt1 is a major regulator of tumour angiogenesis and progression","volume":"5","author":"Wagner","year":"2014","journal-title":"Nat Commun"},{"key":"R30-20230914","doi-asserted-by":"crossref","first-page":"13885","DOI":"10.1073\/pnas.0405884101","article-title":"Induction of WT1 (Wilms\u2019 tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression","volume":"101","author":"Oka","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"R31-20230914","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00432-012-1348-2","article-title":"WT1 peptide immunotherapy for gynecologic malignancies resistant to conventional therapies: a phase II trial","volume":"139","author":"Miyatake","year":"2013","journal-title":"J Cancer Res Clin Oncol"},{"key":"R32-20230914","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00262-015-1674-8","article-title":"Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response","volume":"64","author":"Hashimoto","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"R33-20230914","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1158\/2326-6066.CIR-17-0386","article-title":"Combination gemcitabine and WT1 peptide vaccination improves progression-free survival in advanced pancreatic ductal adenocarcinoma: a phase II randomized study","volume":"6","author":"Nishida","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"R34-20230914","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1159\/000481353","article-title":"Wilms\u2019 Tumor Gene 1 (WT1) peptide vaccine therapy for hematological malignancies: from CTL epitope identification to recent progress in clinical studies including a cure-oriented strategy","volume":"40","author":"Oka","year":"2017","journal-title":"Oncol Res Treat"},{"key":"R35-20230914","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2183\/pjab.74.50","article-title":"Immuno-friendly use of BCG-cell-wall skeleton remarkably improves the survival rate of various cancer patients","volume":"74","author":"Hayashi","year":"1998","journal-title":"Proc Japan Acad"},{"key":"R36-20230914","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1111\/cas.12824","article-title":"Adjuvant for vaccine immunotherapy of cancer--focusing on Toll-like receptor 2 and 3 agonists for safely enhancing antitumor immunity","volume":"106","author":"Seya","year":"2015","journal-title":"Cancer Sci"},{"key":"R37-20230914","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1093\/annonc\/mdr363","article-title":"An intra-patient placebo-controlled phase I trial to evaluate the safety and tolerability of intradermal IMM-101 in melanoma","volume":"23","author":"Stebbing","year":"2012","journal-title":"Ann Oncol"},{"key":"R38-20230914","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1038\/bjc.2016.342","article-title":"Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer","volume":"115","author":"Dalgleish","year":"2016","journal-title":"Br J Cancer"},{"key":"R39-20230914","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/s12967-018-1602-8","article-title":"Enhanced effect of checkpoint inhibitors when given after or together with IMM-101: significant responses in four advanced melanoma patients with no additional major toxicity","volume":"16","author":"Dalgleish","year":"2018","journal-title":"J Transl Med"},{"key":"R40-20230914","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1272\/jnms1923.38.267","article-title":"Treatment of malignant tumors by an extract from tubercle bacilli (tuberculosis vaccine)","volume":"38","author":"Maruyama","year":"1971","journal-title":"Nihon Ika Dagaku Zasshi"},{"key":"R41-20230914","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1684\/ejd.2011.1619","article-title":"Vaccination with WT-1 (Wilms\u2019 tumor gene-1) peptide and BCG-CWS in melanoma","volume":"22","author":"Nishioka","year":"2012","journal-title":"Eur J Dermatol"},{"key":"R42-20230914","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1111\/j.1349-7006.2009.01271.x","article-title":"Immunotherapy of ovarian cancer with cell wall skeleton of Mycobacterium bovis Bacillus Calmette-Gu\u00e9rin: effect of lymphadenectomy","volume":"100","author":"Hayashi","year":"2009","journal-title":"Cancer Sci"},{"key":"R43-20230914","doi-asserted-by":"crossref","first-page":"6541","DOI":"10.1182\/blood-2009-02-202598","article-title":"A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS","volume":"113","author":"Keilholz","year":"2009","journal-title":"Blood"},{"key":"R44-20230914","doi-asserted-by":"crossref","first-page":"13824","DOI":"10.1073\/pnas.1008051107","article-title":"Induction of complete and molecular remissions in acute myeloid leukemia by Wilms\u2019 tumor 1 antigen-targeted dendritic cell vaccination","volume":"107","author":"Van Tendeloo","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R45-20230914","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2017-04-780155","article-title":"Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia","volume":"130","author":"Anguille","year":"2017","journal-title":"Blood"},{"key":"R46-20230914","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1111\/cas.13409","article-title":"Phase 1\/2 study of the WT1 peptide cancer vaccine WT4869 in patients with myelodysplastic syndrome","volume":"108","author":"Ueda","year":"2017","journal-title":"Cancer Sci"},{"key":"R47-20230914","doi-asserted-by":"crossref","first-page":"7483","DOI":"10.1158\/1078-0432.CCR-17-2169","article-title":"A randomized phase ii trial of adjuvant galinpepimut-S, WT-1 analogue peptide vaccine, after multimodality therapy for patients with malignant pleural mesothelioma","volume":"23","author":"Zauderer","year":"2017","journal-title":"Clin Cancer Res"},{"key":"R48-20230914","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1182\/bloodadvances.2017014175","article-title":"Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia","volume":"2","author":"Maslak","year":"2018","journal-title":"Blood Adv"},{"key":"R49-20230914","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrmicro1681","article-title":"The perfect mix: recent progress in adjuvant research","volume":"5","author":"Guy","year":"2007","journal-title":"Nat Rev Microbiol"},{"key":"R50-20230914","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1517\/17425240903018863","article-title":"Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators","volume":"6","author":"Nordly","year":"2009","journal-title":"Expert Opin Drug Deliv"},{"key":"R51-20230914","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/jnci\/52.1.95","article-title":"Biologically active components from mycobacterial cell walls. I. Isolation and composition of cell wall skeleton and component P3","volume":"52","author":"Azuma","year":"1974","journal-title":"J Natl Cancer Inst"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201908160-00031","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T21:58:17Z","timestamp":1694728697000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201908160-00031"}},"subtitle":["A phase 1 study of safety and immunogenicity assessments"],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":50,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000016771","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8]]}}}